###begin article-title 0
The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 276 284 <span type="species:ncbi:9606">patients</span>
The clinical syndrome of thalassemia intermedia (TI) results from the beta-globin genotypes in combination with factors to produce fetal haemoglobin (HbF) and/or co-inheritance of alpha-thalassemia. However, very little is currently known of the molecular basis of Chinese TI patients.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 230 238 <span type="species:ncbi:9606">patients</span>
We systematically analyzed and characterized beta-globin genotypes, alpha-thalassemia determinants, and known primary genetic modifiers linked to the production of HbF and the aggravation of alpha/beta imbalance in 117 Chinese TI patients. Genotype-phenotype correlations were analyzed based on retrospective clinical observations.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 236 245 221 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-3.7 </sup>
###xml 422 423 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
A total of 117 TI patients were divided into two major groups, namely heterozygous beta-thalassemia (n = 20) in which 14 were characterized as having a mild TI with the Hb levels of 68-95 g/L except for five co-inherited alphaalphaalphaanti-3.7 triplication and one carried a dominant mutation; and beta-thalassemia homozygotes or compound heterozygotes for beta-thalassemia and other beta-globin defects in which the beta+-thalassemia mutation was the most common (49/97), hemoglobin E (HbE) variants was second (27/97), and deletional hereditary persistence of fetal hemoglobin (HPFH) or deltabeta-thalassemia was third (11/97). Two novel mutations, Term CD+32(A-->C) and Cap+39(C-->T), have been detected.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 269 270 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 275 277 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 287 288 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 294 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</sup>
###xml 398 399 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 404 405 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
Chinese TI patients showed considerable heterogeneity, both phenotypically and genotypically. The clinical outcomes of our TI patients were mostly explained by the genotypes linked to the beta- and alpha-globin gene cluster. However, for a group of 14 patients (13 beta0/betaN and 1 beta+/betaN) with known heterozygous mutations of beta-thalassemia and three with homozygous beta-thalassemia (beta0/beta0), the existence of other causative genetic determinants is remaining to be molecularly defined.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 255 256 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 280 281 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 450 451 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 452 453 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 473 474 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 1089 1090 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1091 1092 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1028 1036 <span type="species:ncbi:9606">patients</span>
beta-thalassemia is one of the most common monogenic disorders in the world. The incidence for this disease is high in tropical and subtropical areas including southern China. In southern China, the carrier rate of beta-thalassemia is 2.54% in Guangdong [1] and 6.78% in Guangxi [2] where two provinces were thalassemia occurred most frequently. The hemoglobin E (HbE) is one of the common beta-thalassemia variants with carrier rates of 0.09-0.13% [1,3], and 0.19-0.21% [[2], unpuplished report from our laboratory] , respectively, in these two regions. According to the clinical phenotypes, beta-thalassemia can be divided into three main types: thalassemia major (TM), thalassemia trait (TT) and thalassemia intermedia (TI). TM is a severe form that requires transfusions from infancy for survival, whereas TT is usually asymptomatic. TI is used to indicate a clinical condition of intermediate gravity between TT and TM, which encompasses a wide phenotypic spectrum spanning from mild anemia to more severe anemia and these patients require only occasional blood transfusions, if any [4,5].
###end p 10
###begin p 11
###xml 207 208 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 209 210 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 347 348 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 393 394 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 464 466 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 508 515 483 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL11A </italic>
###xml 597 599 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 738 740 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 788 790 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 791 793 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 855 857 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 998 1000 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1011 1013 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1025 1026 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1027 1029 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1042 1044 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1069 1071 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1164 1166 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
###xml 1127 1135 <span type="species:ncbi:9606">patients</span>
###xml 1386 1394 <span type="species:ncbi:9606">patients</span>
###xml 1748 1753 <span type="species:ncbi:9606">human</span>
Corresponding to the phenotypic diversity, the molecular basis of TI is also variable. The major genetic modifiers of beta-thalassemia are genotypes of beta- and alpha-globin and expression of gamma-globin [6,7]. Some genotypic factors have been reported to affect synthesis of the gamma-globin chain, such as the 3'HS1 (+179 C-->T) polymorphism [8], the (AT)xNy(AT)z motif in the 5'HS2 site [9], and the (AT)x(T)y motif in the -540 region of the beta-globin gene[10]. Variation of rs11886868 (T-->C) in the BCL11A gene has also been shown to correlate with increased HbF in European TI patients [11]. In addition, those factors that can moderate globin imbalances indirectly or cause the beta-thalassemia-like phenotype, such as GATA-1 [12], alpha hemoglobin stabilizing protein (AHSP) [13,14], and heme-regulated initiation factor 2 alpha kinase (HRI) [15], are also thought to contribute to the phenotypic diversity of TI. Researchers have described molecular characterization of TI in Iranian [16], Indian [17], Italian [4,18], Israelis [19] and other populations [20]. However, to date, the genetic basis of TI in Chinese patients is still poorly understood [21]. In this study, a comprehensive analysis of the molecular basis underlying TI was performed in southern China. Genotypes of beta-globin and other known modifiers linked to alpha/beta imbalance were investigated in 117 patients with beta-thalassemia intermedia phenotypes. Their clinical, hematological, and molecular data were analyzed systematically with the aim of creating a genotype-phenotype correlation. During the analysis, two novel mutations, Term CD+32(A-->C) and Cap+39(C-->T), were found. These two mutations were named according to the standard nomenclature rules of human hemoglobin mutation . Our findings provide genetic insights of TI occurrence in southern China and are useful in genetic counselling, treatment and management.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Subjects
###end title 13
###begin p 14
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">children</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
A total of 117 patients from 109 families with TI phenotypes were recruited for this study and consisted of the following: 63 males and 54 females, 73 children and 44 adults. 78 patients (66.7%) came from Guangxi, 37 (31.6%) came from Guangdong, and 2 (1.7%) came from either Guizhou or Zhejiang. Their ethnic backgrounds were as follows: 71 Han, 45 Zhuang and 1 Miao. We recruited the TI patients in this study according to previously described criteria [4,5,20], in whom the classical clinical diagnosis of TI patients, such as the steady state Hb level of 60-105 g/L, age at diagnosis over two years old, and transfusion independence were emphasized for all our patients. The protocol for this study was approved by medical ethics committee of Southern Medical University. Informed consent was obtained from each individual or parents of individuals younger than 18 years old.
###end p 14
###begin title 15
Hematological analysis and Clinical data collection
###end title 15
###begin p 16
###xml 176 178 176 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
Hematological data: complete blood counts and red cell indices were determined by automated cell counting (Model Sysmex F-820; Sysmex Co Ltd, Kobe, Japan); the levels of HbA, A2 and F were analyzed on the Bio-Rad Variant II HPLC system (HPLC, VARIANtrade mark, Bio-Rad, Hercules, CA, USA).
###end p 16
###begin p 17
Clinical data: the information about blood transfusions, thalassemia appearance, and age at diagnosis, hepatosplenomegaly and splenectomy was obtained by retrospective clinical data.
###end p 17
###begin title 18
Molecular analysis
###end title 18
###begin p 19
###xml 194 196 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E </sup>
###xml 321 322 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 368 369 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 374 375 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 377 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 391 392 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 407 409 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 486 488 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 539 542 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEA</sup>
###xml 550 554 505 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3.7 </sup>
###xml 564 567 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.2</sup>
###xml 570 571 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 613 617 560 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cd30</sup>
###xml 623 628 566 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cd31 </sup>
###xml 634 638 573 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cd59</sup>
###xml 644 646 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">QS</sup>
###xml 652 654 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CS</sup>
###xml 665 667 592 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WS</sup>
###xml 670 671 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 693 702 608 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-3.7 </sup>
###xml 720 729 623 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-4.2 </sup>
###xml 743 745 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 746 748 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 754 759 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI </italic>
###xml 776 777 679 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 796 798 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 799 801 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 900 901 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 906 907 799 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 915 916 805 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 921 923 808 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 930 931 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 936 938 817 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 984 985 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 990 991 865 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1056 1057 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 1068 1069 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 1229 1236 1093 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL11A </italic>
###xml 1326 1327 1179 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1332 1334 1182 1184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 1341 1342 1188 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1347 1348 1191 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</sup>
###xml 1431 1436 1272 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AHSP </italic>
###xml 1644 1645 1479 1480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1650 1652 1482 1484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 1659 1660 1488 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1665 1667 1491 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 1748 1749 1574 1575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1750 1751 1576 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1752 1753 1578 1579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1754 1756 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1795 1796 1621 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1591 1597 <span type="species:ncbi:10090">murine</span>
DNA analysis: genomic DNA was extracted from peripheral blood by standard phenol/chloroform methods. The 11 known beta-thalassemia mutations including -29(A-->G), -28 (A-->G), CD17 (A-->T), betaE (CD26 G-->A), IVS-1-1(G-->T), IVS-1-5(G-->C), CD27-28(+T), CD41-42 (-CTTT), CD43 (G-->T), CD71-72(+A) and IVS-2- 654(C-->T) [1], the two common deletions including Chinese Ggamma+(Agammadeltabeta0) thalassemia [22] and Southeast Asian hereditary persistence of fetal hemoglobin (SEA-HPFH) [23], the three common alpha-thalassemia deletions (--SEA, -alpha3.7 and -alpha4.2) [1], the six non-deletional mutations (alphacd30,alphacd31 ,alphacd59,alphaQS,alphaCS, and alphaWS) [1], the alphaalphaalphaanti-3.7 or alphaalphaalphaanti-4.2 triplication [24,25] and XmnI site -158 of the Ggamma-globin gene [26,27] were analyzed by previously described methods. Further sequence analysis was applied on both beta0/beta0and beta+/betaN or beta0/betaN samples, analyzed targets for the former (beta0/beta0) include both 3'HS1 and 5'HS2 core region, the promoters of the Ggamma- and Agamma-globin genes, the (AT)x(T)y sequence variations at the position -540 of the beta-globin gene, a single-nucleotide polymorphism (SNP) of rs11886868 in the BCL11A gene, as well as the whole alpha2- and alpha1-globin genes; and those for the latter (beta+/betaN or beta0/betaN) include the core regions of both 5'HS2 and 5'HS3, the whole beta-globin gene and AHSP gene, and the full-lenghth cDNA of GATA-1 generated by RT-PCR from mRNA. Since HRI has been shown to modify the phenotypic severity of beta-thalassemia in murine models, we also sequenced the HRI cDNA in beta+/betaN or beta0/betaN samples by RT-PCR. The PCR primers used in this study were previously published [1,8,9,28] or designed by us as listed in table 1. Each of the above polymorphic loci with repeat motifs in heterozygous individuals was verified by sequencing cloned PCR products.
###end p 19
###begin p 20
Primer sequences and their location
###end p 20
###begin p 21
###xml 82 90 <span type="species:ncbi:9606">patients</span>
The molecular, hematological and clinical data of 117 thalassemia intermedia (TI) patients
###end p 21
###begin p 22
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 25 27 25 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II</bold>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 736 738 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sup>
###xml 832 834 830 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sup>
###xml 847 849 845 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 858 859 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 875 878 869 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3.7</sup>
###xml 885 888 875 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.2</sup>
###xml 891 895 881 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEA </sup>
###xml 904 906 890 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CS</sup>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 422 429 <span type="species:ncbi:9606">patient</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
I: Type I TI (97,82.9%), II: Type II TI (20,17.1%). 1number of patients whose XmnI site were +/+:+/-:-/-:NA(NA, not available); 2number of patients in transfusion (T, transfusion; NT, not transfusion; NA, not available). 3number of patients with splenectomy (S, splenectomy; NS, hepatosplenomegaly but not splenectomy; NH, not hepatosplenomegaly; NA, not available). These three groups of data were described based on the patient's numbers, which were recorded by genotyping of Xmn1 polymorphism (Xmn1) or by positive scoring of recruited patients in clinical data collection (transfusion and splenectomy). The total number of each for these three groups of data should be equal to the number of patients in third colomn of this table. 4 Mean +/- SD of age at diagnosis (years); numbers in brackets indicate the number of patients. 5 Including HbA2 and HbE. 6Including -alpha3.7,-alpha4.2,--SEA and alphaCS
###end p 22
###begin title 23
RNA analysis
###end title 23
###begin p 24
###xml 392 394 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 567 574 <span type="species:ncbi:9606">patient</span>
Total cellular RNA was isolated from fresh peripheral blood using QIAamp RNA Blood Mini Kit (Qiagen, Germany). The cDNA synthesis was performed using the ExScript RT reagent Kit (TaKaRa Biotechnology, China). The expression levels of beta-globin (target gene) and beta-actin (control gene) were measured by SYBR Green-based relative quantitative RT-PCR assays described previously by Yipeng [28]. Five heterozygous subjects carrying the Cap+39(C-->T) mutation and three heterozygous subjects carrying the Term CD+32(A-->C) mutation were selected respectively, as two patient groups, while six normal subjects were used as the control group.
###end p 24
###begin p 25
###xml 178 180 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 301 302 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 318 319 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
beta-globin haplotype analysis: the beta-globin haplotypes associated with the two novel mutations were analyzed with PCR amplification followed by restriction-enzyme digestion [28]. Seven classical polymorphic restriction enzyme sites selected for haplotype analysis were Hinc II-5'epsilon, Hind III-Ggamma, Hind III-Agamma, HincII-psibeta, Hinc II-3'psibeta, Ava II-beta and Bam HI-3'beta. Each individual was scored for the presence (+) or absence (-) of each of the seven RFLP sites.
###end p 25
###begin title 26
Statistical methods
###end title 26
###begin p 27
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistical analysis was performed using SPSS software (Version 13.0, SPSS inc, USA). The difference of the relative mean mRNA concentration between mutation carriers and normal individuals were analyzed by the independent samples t-test. A p-value < 0.05 was considered as statistically significant.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Molecular basis of 117 TI patients in southern China
###end title 29
###begin p 30
###xml 242 243 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 813 815 778 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 932 934 893 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1067 1069 1024 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1145 1147 1098 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1409 1410 1345 1346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1431 1432 1367 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 1437 1438 1369 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1439 1440 1371 1372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 1455 1457 1376 1378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 1464 1465 1385 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
In this study, 117 Chinese individuals between 2 and 60 years of age were enrolled to characterize the molecular basis of beta-thalassemia intermedia in southern China. Their clinical, hematological and molecular data are summarized in table 2. According to their genotype of beta-globin, we divided them into two major types: Type I beta-thalassemia homozygotes or compound heterozygotes for beta-thalassemia and other beta-globin defects (Hb E, HPFH or deltabeta-thalassemia) (n = 97) who inherited two deficient beta-globin alleles and Type II beta-thalassemia heterozygotes (n = 20) who had only a single beta-thalassemia allele. Statistical comparison showed that their steady-state Hb level of Type II (86.7 +/- 10.8 g/L) was significantly higher than that of Type I (75.7 +/- 11.4 g/L) (Mann-Whitney test, p < 0.05). In contrast, their HbF level of Type I (57.9 +/- 27.2%) was much higher than that of Type II (4.0 +/- 3.8%, p = 0.000). Significant differences in hematological parameters such as MCV (66.3 +/- 8.7 fL in Type I vs. 58.7 +/- 6.9 fL in Type II, p = 0.004) and MCH (20.2 +/- 2.5 pg in Type I vs. 18.5 +/- 2.0 pg in Type II, p = 0.000) were also observed. In total, we detected 18 beta-thalassemia alterations including two novel ones which were termed as Term CD +32(A-->C) and Cap+39(C-->T), beta-globin variant HbE, the two deletional mutations which can lead to SEA-HPFH or (deltabeta)0-thalassemia Chinese Ggamma+(Agammadeltabeta)0 (table 3).
###end p 30
###begin p 31
###xml 40 48 <span type="species:ncbi:9606">patients</span>
beta globin mutations identified in 117 patients with TI phenotype.
###end p 31
###begin p 32
###xml 0 4 0 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1,2 </sup>
1,2 Novel mutations found in this study.
###end p 32
###begin p 33
###xml 447 450 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3.7</sup>
###xml 458 461 430 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.2</sup>
###xml 465 469 437 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEA </sup>
###xml 485 487 453 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CS</sup>
###xml 659 662 616 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEA</sup>
###xml 669 672 622 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.2</sup>
###xml 807 816 733 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-3.7 </sup>
###xml 1077 1079 998 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 1109 1111 1030 1032 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 1374 1376 1295 1297 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 1434 1436 1352 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 1471 1473 1386 1388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 1608 1609 1519 1520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 1614 1615 1521 1522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1616 1617 1523 1524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 1632 1634 1528 1530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 1754 1755 1645 1646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 1760 1761 1647 1648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1762 1763 1649 1650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 1778 1780 1654 1656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 1804 1805 1678 1679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 1810 1811 1680 1681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1812 1813 1682 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 1828 1829 1687 1688 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1861 1865 1720 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEA </sup>
###xml 1919 1921 1778 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 906 911 <span type="species:ncbi:9606">child</span>
###xml 1165 1168 <span type="species:ncbi:9606">boy</span>
Type I beta-thalassemia homozygotes or compound heterozygotes for beta-thalassemia and other beta-globin defects were detected in 97 TI patients (82.9%) as follows: (i) Fifty-nine (50.4%) had homozygous or compound heterozygous beta-thalassemia alleles with co-existing normal (44 cases, 37.6%) or mutant (15 cases, 12.8%) alpha-globin genes. Four types of the alpha-thalassemia alterations were identified in our TI patients, including the -alpha3.7, -alpha4.2, --SEA alleles or alphaCSalpha. We observed two TI patients with particular combinations of alpha-globin defects and common beta-globin genotypes. One was caused by co-existence of Hb H disease (--SEA/-alpha4.2) and beta-thalassemia compound heterozygosity CD17 (A-->T)/IVS-2-654 (C-->T), while the other was caused by alphaalpha/alphaalphaalphaanti-3.7 and beta-thalassemia homozygosity of the -28 (A-->G) mutations. The first case was a male child with Hb 66 g/L and a splenectomy, when he was diagnosed at the age of 3 years, he had been received a transfusion only one time. His blood indices showed RBC 4.13x1012/L, MCV51.7fL, MCH16.0 pg, HbA2 4.0%, and HbF38.1%. The second case was a 12-year-old boy who had never been transfused. Pallor, hepatosplenomegaly and slight facial alterations were noted. He had presence of blood indices with microcytic-hypochromic anemia: Hb76 g/L, MCV76.2fL, MCH27.3 pg, HbA2 3.4% and HbF65.2%. (ii) Twenty-seven (23.1%) were HbE/beta0 compound heterozygotes. No HbE/beta+ heterozygote or co-incident alpha-globin mutations were found in this group. (iii) Eleven (9.4%) carried SEA-HPFH (7 cases) or Chinese Ggamma+(Agammadeltabeta)0 (4 cases) deletions in addition to having one beta-thalassemia mutation. Among them, two were IVS-2-654 (C-->T)/Chinese Ggamma+(Agammadeltabeta)0 and -28 (A-->G)/Chinese Ggamma+(Agammadeltabeta)0, respectively, both plus one --SEA deletion, which were first reported by Li in our lab [22].
###end p 33
###begin p 34
###xml 270 279 245 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-3.7 </sup>
###xml 311 320 274 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti-4.2 </sup>
###xml 566 568 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 357 364 <span type="species:ncbi:9606">patient</span>
Type II beta-thalassemia heterozygosity was detected in 20 TI patients (17.1%) as follows: (i) Fourteen (12.0%) carried a single beta-thalassemia allele and normal alpha-globin genes. (ii) Five (4.2%) had a single beta-thalassemia allele and co-inherited alphaalphaalphaanti-3.7 triplication. No alphaalphaalphaanti-4.2 triplication was detected. (iii) One patient (0.9%), in a Miao family, was a heterozygote for a frameshift beta-thalassemia mutation at CD 53 (-T). This mutation is considered to be a dominant form and was first reported by Yi in our lab in 2008[28].
###end p 34
###begin title 35
###xml 41 42 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 47 49 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 60 61 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 66 68 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 75 76 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 81 83 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
Analysis of genotypic modifiers in 3 beta0/beta0 and 10 beta0/betaN or beta+/betaN TI cases
###end title 35
###begin p 36
###xml 39 40 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 45 47 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 130 131 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 136 138 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 203 204 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 428 429 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
Usually, thalassemia patients with beta0/beta0 genotype and normal alpha-globin gene had the TM phenotypes, but we detected 3 beta0/beta0 patients with TI phenotypes whose Hb levels are 74-99 g/L (table 4). We examined the existence of known genetic modifiers, which related to increasing HbF levels in these three cases. The clinical, hematological and molecular results observed from the group of patients are listed in table 4.
###end p 36
###begin p 37
###xml 77 78 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 83 85 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Hematological data and existence of genetic modifiers identified among 3 beta0/beta0 TI patients
###end p 37
###begin p 38
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sup>
###xml 342 349 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL11A </italic>
1 numbers before or after the slash indicate the enlarged liver or spleen in size (cm: centimeter) when first diagnosis. The alpha-globin genotype, the sequence analysis of Agamma-(-500~+223) and Ggamma-(-618~+39) globin genes are all normal in the three samples. The genotypes of both 3'HS1(+179) polymorphic site and rs11886868 SNP site of BCL11A gene are all C/C in the three samples.
###end p 38
###begin p 39
###xml 464 465 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
Fourteen patients who displayed the relative mild TI phenotypes with steady Hb levels of 68-95 g/L were identified to be heterozygotes with one known common mutation for beta-thalassemia and normal alpha-globin gene. Analysis of other known genetic modifiers that mainly focused on several factors of aggravate alpha/beta imbalance were done in ten patients (blood samples from other four patients were not available). The overall findings are summarized in table 5.
###end p 39
###begin p 40
###xml 75 76 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 81 83 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 90 91 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 96 98 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N </sup>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Htological data and existence of genetic modifiers identified among 10 beta+/betaN or beta0/betaN TI patients
###end p 40
###begin p 41
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sup>
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 351 356 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AHSP </italic>
###xml 452 460 <span type="species:ncbi:9606">patients</span>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
1 numbers before or after the slash indicate the enlarged liver or spleen in size (cm: centimeter) when first diagnosis.2 Genotypes of two SNP sites including rs2639 and rs2640 detected in the HRI cDNA. ND: not determined,because of no mRNA available for these samples. The alpha-globin genotype, analysis of core regions of both 5'HS2 and 5'HS3, and AHSP gene are all normal in the tested ten samples. Blood samples from other four out of fourteen TI patients with heterozygous genotypes were not available, thus the later three targets in the table can not be conducted for these four patients.
###end p 41
###begin title 42
Two novel mutations of the beta-globin gene
###end title 42
###begin p 43
###xml 126 127 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
Two novel mutations, Term CD+32(A-->C) (GenBank No: ) and Cap+39(C-->T) (GenBank No: ), were identified in this study (Figure 1).
###end p 43
###begin p 44
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Identification of two novel mutations showing the (A)Term CD+32(A-C) and the (B) Cap+39(C-T). </bold>
###xml 478 488 <span type="species:ncbi:9598">chimpanzee</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 499 504 <span type="species:ncbi:9796">horse</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
###xml 528 537 <span type="species:ncbi:7955">zebrafish</span>
Identification of two novel mutations showing the (A)Term CD+32(A-C) and the (B) Cap+39(C-T). The hematological data and alpha/beta globin genotype of two family members are listed in tables. The probands are labeled by the arrow in the family pedigrees. DNA sequences of sense strand are also shown, downward arrows indicating the mutation nucleotides (overlapping peaks are indicated by N). The alignment of beta-globin sequences are shown on the bottom. (EMBL accession No.: chimpanzee , human , horse , monkey , mouse , and zebrafish ). *(Blood samples not avaiable). T+32: Term CD+32(A-C), 27-28:CD 27-28(+C), +39:Cap+39(C-T), and 41-42: CD 41-42 (-CTTT).
###end p 44
###begin p 45
###xml 96 98 94 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 362 364 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 446 451 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI </italic>
###xml 331 336 <span type="species:ncbi:9606">human</span>
Family A: Term CD+32(A-->C). The proband (AIII1) displayed the TI phenotypes with Hb 72 g/L, HbA2 4.6% and HbF 64.8%. His father was found to have a CD 27-28 (+C) mutation, whereas his mother was found to have a novel mutation of an A-->C substitution at nucleotide position +32 from the stop codon TAA in the 3' UTR region of the human beta-globin gene (Figure 1A). The proband was a compound heterozygote of Term CD+32(A-->C)/CD 27-28(+C) with XmnI (+/+) homozygosity. The haplotypes associated with Term CD+32(A-->C) and CD 27-28(+C) are "--+++-+"and "--++++-", respectively.
###end p 45
###begin p 46
###xml 119 121 117 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 537 543 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xmn I </italic>
###xml 797 800 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++ </sup>
###xml 256 261 <span type="species:ncbi:9606">human</span>
Family B: Cap+39(C-->T). The proband (BIII1) showed a mild TI phenotypes with Hb 105 g/L, MCV 53.7 fL, MCH 17.4 pg, HbA2 5.8%. His father had a novel mutation of a C-->T substitution at nucleotide position +39 from the cap site in the 5' UTR region of the human beta-globin gene. This mutation was likely inherited from his dead grandfather. His mother did not provide her blood sample, but she was an obligate carrier with CD 41-42(-CTTT) mutation since her son (BIII1) was a compound heterozygote of Cap+39(C-->T)/CD 41-42(-CTTT) with Xmn I (-/-) homozygosity. Interestingly, his father (BII3) and four other family members (BII1, BII2, BII4, and BIII2) were all heterozygotes of Cap+39 (C-->T) mutations. Since they do not have any evident hematologic phenotype, we regard this mutation as beta++ (silent beta-thalassemia).
###end p 46
###begin p 47
###xml 412 414 412 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
Sequence alignment showed that Term CD+32(A) and Cap+39(C) were conserved sites during evolution (Figure.1). In addition, we randomly choosed 156 cases normal individuals from Guangxi as control samples and excluded the possibility of that the two new mutations were polymorphic sites. These control samples are 13-19 years old with Hb (130-152 g/L), MCV (83-100 fL), MCH (28-33.8 pg), HbA (96.54-97.94%) and HbA2 (2.06-3.46%).
###end p 47
###begin p 48
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y </italic>
###xml 96 98 96 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x </italic>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 109 111 109 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </italic>
###xml 109 111 109 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>2 </italic></sup>
###xml 145 147 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y </italic>
###xml 155 156 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 165 166 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 166 168 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </italic>
###xml 166 168 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>2 </italic></sup>
###xml 258 260 250 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n </italic>
###xml 314 316 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n </italic>
###xml 371 373 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n </italic>
###xml 543 545 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 837 839 813 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 708 715 <span type="species:ncbi:9606">patient</span>
Real-time PCR was used to analyze the mRNA level. Two standard curves were generated: y = -3.672x + 19.787 (R2 = 0.999) for beta-globin mRNA and y = -3.466x+24.000 (R2 = 0.999) for beta-actin mRNA. The mean relative mRNA concentrations were 0.835 +/- 0.048 (n = 3) for the Term CD+32(A-->C) group, 1.093 +/- 0.118(n = 5) for the Cap+39(C-->T) group, and 1.016 +/- 0.098 (n = 6) for the normal control group after a normalization procedure using linear regression equations. Statistical analysis showed that there was a significant difference (p = 0.021) of mean relative beta-globin mRNA concentration between the Term CD+32(A-->C) group and the control group. The decreased level of beta-globin mRNA in the patient group compared with that of the normal control group was calculated to be 17.8%. In contrast, no significant difference (p = 0.270) was found between the Cap+39(C-->T) group and the control group.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1493 1494 1492 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1495 1496 1494 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1497 1498 1496 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1864 1866 1860 1862 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 871 879 <span type="species:ncbi:9606">patients</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
###xml 941 948 <span type="species:ncbi:9606">patient</span>
###xml 977 984 <span type="species:ncbi:9606">patient</span>
###xml 1248 1256 <span type="species:ncbi:9606">patients</span>
###xml 1545 1552 <span type="species:ncbi:9606">patient</span>
###xml 1576 1583 <span type="species:ncbi:9606">patient</span>
###xml 1831 1839 <span type="species:ncbi:9606">patients</span>
###xml 1869 1877 <span type="species:ncbi:9606">patients</span>
Provision of appropriate treatment and management for TI patients is still a challenge because its characteristic features, phenotypic diversity, and genotypic heterogeneity, the clinical severity of thalassemia intermedia cases are very difficult to predict from their genotypic data. The molecular mechanisms underlying different populations in Europe [18,20], Israel [19], India [17] and Iran [16] had been reported. However, the molecular basis of Chinese TI patients was still uncertain, which brought about much trouble for Chinese doctors in offering genetic counselling, treatment and management. The present phenotype-genotype correlation data observed from 117 Chinese TI patients could provide solid basis for improving the understanding this problem (table 2). On the basis of the clinical pictures and statistical results of hematological parameters, type I patients were more clinically severe than type II patients. This is a patient-based study in which the in-patient samples were recruited during the period of about 2 years from Guangxi and Guangdong Provinces, where the thalassemia are most endemic in southern China. We believe that the molecular basis of TI obtained from this study should be generalizable to the Chinese TI patients of the various regions in southern China because the differences between regions in southern China for the ss-thalassemia mutation spectrum in the southern Chinese are not statistically significant according to previously observations [1-3,5]. However, there were some milder forms of TI patient's samples who were out-patient we might have missed and most of heterozygotes (10/14) whose negative results could not be explained were detected in Guangxi, two limitations of our study should be noted: (1) Maybe there was a broad spectrum of genetic defects in the Chinese TI patients, such as no the HbE/beta+ TI patients could be identified in our cohort. (2) The finding of heterozygotes with TI phenotype might not provide representitive profile in the Chinese population.
###end p 50
###begin p 51
###xml 207 208 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 382 383 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 388 390 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 409 410 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 415 417 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 531 532 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 559 560 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 846 847 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 854 804 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 861 862 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 867 868 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 947 952 889 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI </italic>
###xml 1056 1061 998 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI </italic>
###xml 1226 1228 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1322 1327 1264 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI </italic>
###xml 1341 1343 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1809 1811 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1925 1927 1845 1847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1954 1956 1871 1873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 2031 2033 1945 1947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 2060 2062 1974 1976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2089 2091 2000 2002 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 2375 2377 2283 2285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2378 2380 2286 2288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 2425 2427 2330 2332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 2563 2564 2468 2469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 2768 2770 2667 2669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2771 2773 2670 2672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 2896 2898 2792 2794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2899 2901 2795 2797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 2902 2904 2798 2800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
###xml 907 914 <span type="species:ncbi:9606">patient</span>
###xml 1199 1207 <span type="species:ncbi:9606">patients</span>
###xml 1253 1261 <span type="species:ncbi:9606">patients</span>
###xml 1785 1793 <span type="species:ncbi:9606">patients</span>
###xml 1892 1900 <span type="species:ncbi:9606">patients</span>
###xml 2009 2017 <span type="species:ncbi:9606">patients</span>
###xml 2160 2166 <span type="species:ncbi:9606">people</span>
###xml 2430 2438 <span type="species:ncbi:9606">patients</span>
###xml 2925 2933 <span type="species:ncbi:9606">patients</span>
According to our molecular analysis, three main characteristic features of Chinese TI patients were found. First, the homozygous or compound heterozygous forms with minor beta-thalassemia mutations (the beta+-thalassemia alleles) were a common pathogenetic mechanism of disease in Chinese TI patients, in which 49 out of 59 patients was found to having beta-globin genotypes of beta+/beta+ (11 cases) and beta+/beta0 (38 cases), among them 41 with co-existing normal alpha-globin genes and 8 with mutant alpha-globin allele (table 2). In other words, the beta+-thalassemia mutation is a major contribution of genes to the Chinese TI patients. In addition to this, additional an alpha-thalassemia defects may reduce the severity of homozygous beta-thalassemia. We observed 14 such cases (23.7%, 14/59) with co-inheritance of beta-thalassemia (beta+/beta+ or beta+/beta0) and alpha-thalassemia defects in the patient group. Second, the affect of an XmnI polymorphism in increasing HbF levels was not as important as it was in other populations. The ratio of XmnI [(+/+), (+/-), (-/-) and (NA, not available)] pattern was detected to be [1:30:75:11] in 117 cases, while the same ratio in 52 Iranian TI patients was [20:20:10:2] [16]. In India, among 73 TI patients, 20 of them (27.4%) were confirmed to be homozygous for the XmnI polymorphism [17]. Third, the molecular mechanism of more than half of the thalassemia heterozygote cases (14/20) was unexplained. Twenty individuals carried only one beta-thalassemia allele: one (5%) was dominantly inherited; five (25%) had co-inherited triplicated alpha-globin genes; and 14 (70%) had normal alpha-globin genes. In contrast, the alpha-globin gene triplication was determined to be the predominant factor of Indian heterozygous thalassemia patients (14/23 cases) [17]. In Ho's research, among 22 heterozygous beta-thalassemia intermedia cases, 10 patients had alpha triplication [20]. Furthermore, no HbE/beta+ heterozygote was observed in our cases while 9/45 TI patients were HbE/beta+ heterozygotes in Thailand [29], suggesting that HbE/beta+ heterozygosity perhaps displayed a more milder form of TI in Chinese people, which would help doctors in providing appropriate genetic counselling. HbE/beta-thalassemia results in a varied clinical expression ranging from severe transfusion dependence to a complete lack of symptoms [29,30]. In this study, there are 27 cases HbE/beta0 TI patients whose clinical phenotypes including Hb levels, transfusion, splenectomy, age at diagnosis, and so on, varies greatly (table 2). It is very difficult to predict the clinical phenotype of the HbE/beta-thalassemia although it was reported that a system for classifying disease severity of HbE/beta-thalassemia had been constructed [29,31]. The possible genetic mechanisms for phenotypic diversity of HbE/betathalassemia have been analyzed in some literatures [29,30,32]. We also found two patients that were compounds of beta-thalassemia, deltabeta-thalassemia and alpha-thalassemia genes. This was rarely reported in other ethnicities.
###end p 51
###begin p 52
###xml 10 11 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 16 18 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 </sup>
###xml 195 196 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 287 288 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 299 300 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sup>
###xml 342 346 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XmnI</italic>
###xml 541 542 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 543 545 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 935 936 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 941 942 913 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 950 951 919 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 956 957 922 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1059 1060 1025 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 1061 1063 1027 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1067 1070 1033 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11 </sub>
###xml 1106 1107 1072 1073 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 1110 1112 1076 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sub>
###xml 1199 1200 1165 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1201 1203 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 812 818 <span type="species:ncbi:9606">people</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
Three beta0/beta0 TI patients with normal alpha-globin gene remained unexplained despite extensive effort to examine the existence of known genetic modifiers linked to increase HbF levels (table 4). The non-deletional forms of HPFH were excluded in sequencing the promoter region of the Ggamma- and Agamma-globin genes. Two cases were +/- of XmnI, which partially, but not completely explains the high level of HbF. The 3'HS1 (+179 C-->T) and rs11886868 (T-->C) variations were shown to correlate with increased HbF in European TI patients [8,11]. The three patients all had C/C genotypes of both at +179 of 3'HS1 and rs11886868. However, we could not consider that C/C genotypes of rs11886868 contributed to the high HbF level based on two facts. One is that the frequency of C/C genotypes was 0.867 in Chinese people from the HapMap data . The second is that an additional 115 samples were analyzed, including 30 TI patients (25 beta0/beta+, 5 beta+/beta+) and 85 normal individuals, in which all were found to be the C/C genotype (data not shown). The (AT)8N12(AT)11 motif in the 5'HS2 site and the (AT)9(T)5 motif in the -540 region had been previously found to be associated with elevated HbF [9,10], but we did not find them in the 3 cases.
###end p 52
###begin p 53
###xml 651 652 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 810 812 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 881 883 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 893 895 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1100 1102 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1887 1889 1852 1854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 77 84 <span type="species:ncbi:9606">patient</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 1031 1037 <span type="species:ncbi:10090">murine</span>
We found 14 patients with heterozygous for beta-thalassemia among our 117 TI patient cohort, in whom the beta-globin gene was found to be structurally intact by sequence analysis and the second alpha-globin gene triplication was excluded. They mostly manifested a relatively mild form of TI because of the Hb levels being 68-95 g/L, the average age at diagnosis being 7.5 +/- 5.1 (years), no blood transfusion or occasionally received (1/14) and mild hepatosplenomegaly (5/14). As for the underlying defective targets, we focused on primary genetic modifiers that could modulate the imbalance of alpha/beta for investigation in ten TI patients (table 5). We evaluated the effects of some potential modifiers involving one linked to the beta-globin gene cluster, the LCR resides in the 5'HS2 and 5'HS3 regions [33], and three ones not to be linked to the beta-globin cluster, AHSP [14], GATA-1[12] and HRI. The later is a kinase that can be inactivated by hemin, which is very recently reported to modify the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia [15]. Sequence analysis of the core regions of 5'HS2 and 5'HS3 showed wild type sequences, thus excluded the possibility that mutations in these control regions reducing the expression of beta-globin gene. No mutations in the cDNA sequences of both AHSP and GATA-1 have been found. In the case of HRI, the polymorphism of rs2639 and rs2640 were detected. The rs2639 (A-->G) is a synonymous mutation and the rs2640 (A-->G) is a missense mutation resulting in a K558R substitution. However, the affect on the function of this substitution is unknown since Lys (K) and Arg (R) are similar in amino acid properties. These results indicate the existence of causative genetic determinants have not been defined molecularly, in agreement with the similar conclusion from Rosatelli's experiment [34] although there were a few differences between the candidate targets for these two studies.
###end p 53
###begin p 54
###xml 73 78 <span type="species:ncbi:9606">human</span>
In this study, we reported two novel mutations in the UTR regions of the human beta-globin gene (Figure.1). The Term CD+32(A-->C) mutation slightly reduced beta-globin mRNA levels to 17.8% less than the normal level. The reduced beta-globin mRNA levels were not detected in the individuals with Cap+39(C-->T) mutation. The detailed mechanisms of two novel mutations are not clear at present. Functional experiments, such as analysis of mRNA stability and trafficking in erythrocytic cells should be performed in the future.
###end p 54
###begin title 55
Conclusions
###end title 55
###begin p 56
###xml 540 542 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 593 595 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 662 664 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 692 694 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
Chinese TI patients showed a high degree of heterogeneity in both phenotypic and genotypic aspects. Some cases could not be explained according to the present data. A more detailed analysis of genetic modifiers modulating the imbalance of alpha/beta will provide more insight into the recognition of thalassemia intermedia. Moreover, other potential genetic determinants which have been demonstrated in cancers and single gene disorders including alpha- and beta-thalassemia, such as a gain-of-function regulatory SNP in a nongenic region [35], loss of heterozygosity in the beta-globin gene [36], segmental duplications involving the alpha-globin gene cluster [37], uniparental disomy event[38], DNA methylation and chromatin alterations, should also be considered.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 266 274 <span type="species:ncbi:9606">patients</span>
WC, XZ and XS contributed equally to the work. XX conceived and designed the study and manuscript revision. WC designed and performed the whole experiments, analyzed the data and wrote the manuscript. XZ collected and analyzed clinical and hematological data of the patients. XS participated in analyzing the results and writing the manuscript. RC and TZ assisted in blood sample collection and clinical data analysis. LL, MS and FX participated in partial molecular experiments. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Pre-publication history
###end title 61
###begin p 62
The pre-publication history for this paper can be accessed here:
###end p 62
###begin p 63

###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
We thank Dr DJ Weatherall for helpful comments and discussion. We also thank Dr.M Qi for excellent suggestions for improving the manuscript. This study was supported in part by the National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund (contract/grant number U0632005) and by the NSFC (contract/grant number 30600359).
###end p 65
###begin article-title 66
The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening
###end article-title 66
###begin article-title 67
Prevalence survey and molecular characterization of alpha and beta thalassemia in Liuzhou city of Guangxi
###end article-title 67
###begin article-title 68
Carrier screening for alpha- and beta-thalassemia in pregnancy: the results of an 11-year prospective program in Guangzhou Maternal and Neonatal hospital
###end article-title 68
###begin article-title 69
Thalassemia intermedia
###end article-title 69
###begin article-title 70
Genetic modifiers of beta-thalassemia
###end article-title 70
###begin article-title 71
Genetic modifiers of the beta-haemoglobinopathies
###end article-title 71
###begin article-title 72
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Increased gamma-globin gene expression in beta-thalassemia intermedia patients correlates with a mutation in 3'HS1
###end article-title 72
###begin article-title 73
Genotypic heterogeneity and correlation to intergenic haplotype within high HbF beta-thalassemia intermedia
###end article-title 73
###begin article-title 74
Influence of Ggamma-158C --> and beta- (AT)x(T)y globin gene polymorphisms on HbF levels in Italian beta-thalassemia carriers and wild-type subjects
###end article-title 74
###begin article-title 75
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia
###end article-title 75
###begin article-title 76
X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction
###end article-title 76
###begin article-title 77
An abundant erythroid protein that stabilizes free alpha-haemoglobin
###end article-title 77
###begin article-title 78
Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia
###end article-title 78
###begin article-title 79
###xml 68 74 <span type="species:ncbi:10090">murine</span>
Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia
###end article-title 79
###begin article-title 80
Molecular mechanisms underlying thalassemia intermedia in Iran
###end article-title 80
###begin article-title 81
Molecular characterization of thalassemia intermedia in Indians
###end article-title 81
###begin article-title 82
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Molecular characterization of beta-thalassemia intermedia in patients of Italian descent and identification of three novel beta-thalassemia mutations
###end article-title 82
###begin article-title 83
Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype
###end article-title 83
###begin article-title 84
Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?
###end article-title 84
###begin article-title 85
Molecular analysis of beta-thalassemia intermedia in Guangdong Province
###end article-title 85
###begin article-title 86
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Two thalassemia intermedia patients with delta beta/beta-thalassemia and a deletional type alpha-thalassemia
###end article-title 86
###begin article-title 87
Molecular characterization and PCR detection of a deletional HPFH: application to rapid prenatal diagnosis for compound heterozygotes of this defect with beta-thalassemia in a Chinese family
###end article-title 87
###begin article-title 88
Single-tube multiplex-PCR screen for anti-3.7 and anti-4.2 alpha-globin gene triplications
###end article-title 88
###begin article-title 89
###xml 131 138 <span type="species:ncbi:9606">patient</span>
Thalassemia intermedia as a result of heterozygosis for beta 0 -thalassemia and alpha alpha alpha anti-3,7 genotype in a Brazilian patient
###end article-title 89
###begin article-title 90
The molecular basis of HPFH in a British family identified by heteroduplex formation
###end article-title 90
###begin article-title 91
Association of -158 (C --> T) (XmnI) DNA polymorphism in G gamma-globin promoter with delayed switchover from fetal to adult hemoglobin synthesis
###end article-title 91
###begin article-title 92
Identification of a novel frameshift mutation at codon 53 (-T) in the beta-globin gene causing dominantly inherited beta-thalassemia in a Chinese Miao family
###end article-title 92
###begin article-title 93
Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-beta-thalassemia in Northeast Thailand
###end article-title 93
###begin article-title 94
The hemoglobin E syndromes
###end article-title 94
###begin article-title 95
A scoring system for the classification of beta-thalassemia/Hb E disease severity
###end article-title 95
###begin article-title 96
Studies in haemoglobin E beta-thalassaemia
###end article-title 96
###begin article-title 97
Locus control regions
###end article-title 97
###begin article-title 98
Thalassaemia-like carriers not linked to the beta-globin gene cluster
###end article-title 98
###begin article-title 99
###xml 26 31 <span type="species:ncbi:9606">human</span>
A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter
###end article-title 99
###begin article-title 100
A novel mechanism for thalassaemia intermedia
###end article-title 100
###begin article-title 101
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients
###end article-title 101
###begin article-title 102
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor
###end article-title 102

